GO
Loading...

Medicine

More

  • Dec 24- The U.S. Food and Drug Administration approved a drug to treat dementia in Alzheimer's patients that was developed by Actavis Plc and Adamas Pharmaceuticals Inc.. Memantine is the active ingredient in Actavis' Namenda, while donepezil is the active ingredient in Pfizer Inc's Aricept. Dublin, Ireland- based Actavis said it expects to launch Namzaric in...

  • Actavis, Adamas win FDA approval for Alzheimer's drug Wednesday, 24 Dec 2014 | 8:20 AM ET

    Dec 24- The U.S. Food and Drug Administration approved a drug to treat dementia in Alzheimer's patients that was developed by Actavis Plc and Adamas Pharmaceuticals Inc.. The drug, Namzaric, is designed to treat moderate-to-severe dementia in Alzheimer's patients who are stabilized with other drugs. Namzaric combines two ingredients in drugs often...

  • Stryker maps out takeover plan of British giant Wednesday, 24 Dec 2014 | 8:08 AM ET
    Stryker's Trevo XP ProVue Retriever is designed to capture and remove the clots and restore blood flow to the brain.

    Stryker, a U.S.-based surgical implant maker, is mapping out a takeover of Smith & Nephew, a British medical device maker.

  • New injectable weight-loss drug approved by FDA Wednesday, 24 Dec 2014 | 7:20 AM ET
    An employee works on a high speed production line of insulin at a factory of Novo Nordisk

    The Food and Drug Administration approved Novo Nordisk's obesity-treating injectable drug, Saxenda.

  • Safeway pulls caramel apples amid listeria scare Tuesday, 23 Dec 2014 | 5:23 PM ET

    LOS ANGELES— Safeway has pulled prepackaged caramel apples from its shelves, the grocery chain said Tuesday, a day after the family of a person who died from a listeria infection linked to the fruit sued the company. Shirlee Jean Frey, who died Dec. 2, became ill after buying several caramel apples from a Safeway supermarket in Felton in October, according to the suit...

  • FDA approves Novo Nordisk's injection for obesity Tuesday, 23 Dec 2014 | 5:14 PM ET

    Dec 23- The U.S. health regulator approved a formulation of Novo Nordisk's diabetes drug, liraglutide, for treating patients of obesity, a disease that affects one in three Americans. Saxenda's rivals include Vivus Inc's Qsymia and Arena Pharmaceuticals Inc's Belviq, which are taken orally. A study showed that half the patients given Saxenda lost at least 5...

  • FDA clears Novo Nordisk's weight loss drug Saxenda Tuesday, 23 Dec 2014 | 4:29 PM ET

    NEW YORK— The Food and Drug Administration has approved a Novo Nordisk diabetes drug as a treatment for obesity. The FDA approved liraglutide in 2010 as a treatment for type 2 diabetes, and Novo Nordisk sells it under the name Victoza as a treatment for that condition. It cleared Vivus Inc.' s Qsymia and Arena Pharmaceuticals Inc.' s Belviq in 2012 and granted...

  • Hepatitis C drug wars  Tuesday, 23 Dec 2014 | 3:00 PM ET

    The battle to limit the sky-high cost of treating hepatitis C is heating up after Express Scripts announced it will put its weight behind a drug made by AbbVie and it will no longer cover Gilead's Sovaldi.

  • Scientific evidence shows the move will not create risks for the nation's blood supply, the FDA said. The FDA said the move aligns the policy for gay men with that for other men and women who are at increased risk for HIV infection. The FDA said it will issue draft guidance on the policy, hopefully early in 2015. It would then review the comments and issue final...

  • Gel stops bleeding instantly  Tuesday, 23 Dec 2014 | 1:42 PM ET

    Vetigel is a plant-based get that stops internal and external bleeding in seconds. Suneris CEO and co-founder Joe Landolina provides perspective on the innovation.

  • The new policy would put the U.S. in line with other countries including Australia, Japan and the U.K.. But many medical groups, including the American Medical Association, say the policy is no longer supported by science, given advances in HIV testing. The agency will recommend the switch in draft guidelines early next year and move to finalize them after taking...

  • Dec 23- BioCryst Pharmaceuticals Inc said its experimental broad-spectrum antiviral drug showed promise against Ebola when tested in monkeys. The U.S. National Institutes of Health is funding the development of the intramuscular formulation of the drug, BCX4430, which is also being tested in an early-stage trial in healthy volunteers.

  • President Barack Obama speaking at the end of the year press conference in the White House, Washington, December 19, 2014.

    The investigation will see if insurance companies discriminated against people with costly chronic conditions. The NYT reports.

  • FDA approves new melanoma drug from Bristol-Myers Monday, 22 Dec 2014 | 4:23 PM ET

    WASHINGTON— The Food and Drug Administration granted accelerated approval Monday to a new drug from Bristol-Myers Squibb to treat the deadliest form of skin cancer. Since 2011, the FDA has approved seven new drugs for the form of skin cancer, including Opdivo. FDA regulators cleared the drug for patients who have previously been treated with an older...

  • Dec 22- The U.S. Food and Drug Administration approved Bristol-Myers Squibb Co's skin cancer drug, more than three months before the scheduled review date. The drug is the second PD-1 inhibitor to be approved by the FDA, the first being Merck& Co Inc's Keytruda in September. The FDA was scheduled to review the drug on March 30.

  • FDA approves Bristol-Myer's skin cancer drug Monday, 22 Dec 2014 | 2:32 PM ET

    Dec 22- The U.S. Food and Drug Administration granted an accelerated approval to Bristol-Myers Squibb Co's drug for an advanced form of skin cancer. The drug, Opdivo, inhibits the action of the protein PD-1, which prevents the body's immune system from attacking melanoma tumors. The FDA's approval comes well before its scheduled review date of March 30.

  • Dec 22- Hong Kong said Monday it has suspended imports of certain U.S. poultry and poultry products because strains of avian influenza have been identified in the United States, marking the second foreign market to issue such a ban. No human cases involving either viral strain have been detected in the United States or Canada, and there are no immediate public...

  • *Company to test combination hep C drug in 2015. Dec 22- Data from Achillion Pharmaceuticals Inc's hepatitis C drug trials showed the company could develop a shorter-duration treatment rivaling offerings from Gilead Sciences Inc and Abbvie Inc.. The biotechnology company's shares rose as much as 17 percent to $16.77, their highest in more than seven years.

  • Achillion rises on new hepatitis C drug study Monday, 22 Dec 2014 | 11:34 AM ET

    NEW YORK— Shares of Achillion Pharmaceuticals advanced Monday after the company said a combination of two experimental hepatitis C drugs cured all patients in a small clinical trial. Shares of Achillion Pharmaceuticals Inc. climbed $1.56, or 11 percent, to $15.77 in morning trading. The New Haven, Connecticut, company plans to start larger clinical trials of...

  • TORONTO, Dec 22- Tekmira Pharmaceuticals Corp will supply one of its experimental Ebola treatments for clinical studies to be conducted in West Africa by a consortium that includes England's Oxford university, the Canadian company said on Monday. The Tekmira treatment targets the Ebola-Guinea virus variant, responsible for the worst Ebola outbreak on...